Abstract
Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 663-670 |
| Number of pages | 8 |
| Journal | Ryumachi |
| Volume | 35 |
| Issue number | 4 |
| Publication status | Published - 1995 |
| Externally published | Yes |
Fingerprint
Keywords
- life table method
- long term treatment
- methotrexate
- rheumatoid arthritis
- salazosulfapyridine
ASJC Scopus subject areas
- Rheumatology
Cite this
Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis. / Ichikawa, Y.; Shinozawa, T.; Yoshida, Tadashi; Kameda, H.; Suzuki, Y.; Kawai, S.; Yamada, H.; Matsuda, T.
In: Ryumachi, Vol. 35, No. 4, 1995, p. 663-670.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Methotrexate and salazosulfapyridine in the long term treatment of rheumatoid arthritis
AU - Ichikawa, Y.
AU - Shinozawa, T.
AU - Yoshida, Tadashi
AU - Kameda, H.
AU - Suzuki, Y.
AU - Kawai, S.
AU - Yamada, H.
AU - Matsuda, T.
PY - 1995
Y1 - 1995
N2 - Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.
AB - Long term treatment of 190 cases of rheumatoid arthritis with either methotrexate or salazosulfapyridine was analyzed for their efficacy and adverse effects. Both treatment groups showed improvement of clinical symptoms, erythrocyte sedimentation rate, and CRP after 1 month of treatment, while RAHA titers decreased significantly after several months. Erythrocyte sedimentation rate and CRP of salazo-sulfapyridine group, once improved, deteriorated again after 12 months of treatment, while methotrexate group showed sustained improvement for 48 months. Radiologic progression estimated according to JF Fries was significantly less in MTX group than in SASP group. Life table analysis showed that the overall probability of continuing methotrexate or salazosulfapyridine at 4 years was 63% and 55%, respectively. The main reason of treatment termination in methotrexate group was adverse effects, while that in salazo-sulfapyridine group was inefficacy.
KW - life table method
KW - long term treatment
KW - methotrexate
KW - rheumatoid arthritis
KW - salazosulfapyridine
UR - http://www.scopus.com/inward/record.url?scp=0029154448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029154448&partnerID=8YFLogxK
M3 - Article
C2 - 7482063
AN - SCOPUS:0029154448
VL - 35
SP - 663
EP - 670
JO - Ryumachi
JF - Ryumachi
SN - 0300-9157
IS - 4
ER -